CBL-B inhibitor-treated autologous tumor-infiltrating lymphocytes DeTIL-0255

A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from a patient's tumor that have been treated ex vivo during cell expansion with NX-0255, an inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), with potential immunomodulating and antineoplastic activities. Upon administration, the CBL-B inhibitor-treated autologous TILs DeTIL-0255 specifically recognize and kill the patient's tumor cells. NX-0255 enhances TIL expansion and the tumor-killing ability of the TILs when returned to the patient.